Filing Details
- Accession Number:
- 0001209191-21-020207
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-03-12 16:52:07
- Reporting Period:
- 2021-03-11
- Accepted Time:
- 2021-03-12 16:52:07
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1490978 | Schrodinger Inc. | SDGR | Pharmaceutical Preparations (2834) | 954284541 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1797782 | Jorg Weiser | C/O Schrodinger, Inc., 120 West 45Th Street, 17Th Floor New York NY 10036 | Evp & Managing Director | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2021-03-11 | 8,659 | $3.07 | 175,875 | No | 4 | M | Direct | |
Common Stock | Disposition | 2021-03-11 | 8,659 | $82.00 | 167,216 | No | 4 | S | Direct | |
Common Stock | Acquisiton | 2021-03-11 | 3,924 | $4.34 | 171,140 | No | 4 | M | Direct | |
Common Stock | Disposition | 2021-03-11 | 3,924 | $82.00 | 167,216 | No | 4 | S | Direct | |
Common Stock | Disposition | 2021-03-11 | 3,800 | $82.00 | 163,416 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (right to buy) | Disposition | 2021-03-11 | 8,659 | $0.00 | 8,659 | $3.07 |
Common Stock | Stock Option (right to buy) | Disposition | 2021-03-11 | 3,924 | $0.00 | 3,924 | $4.34 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
18,095 | 2026-05-10 | No | 4 | M | Direct | |
16,141 | 2028-11-29 | No | 4 | M | Direct |
Reported Non-Derivative Holdings
Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
---|---|---|---|
Common Stock | 17,390 | Indirect | BY ANTERIO CONSULT AND RESEARCH GMBH |
Footnotes
- These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 1, 2020.
- The shares are beneficially owned by Anterio Consult & Research GmbH ("Anterio"). Dr. Weiser is a shareholder and former managing director of Anterio and disclaims beneficial ownership of the shares held by Anterio, except to the extent of his pecuniary interest therein, if any.
- The option was granted on May 11, 2016 and is fully vested.
- This option was granted on November 29, 2018. The shares underlying the option vested with respect to 25% of the shares on December 31, 2019 and the remainder are scheduled to vest in equal monthly installments through December 31, 2022.